rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Lantern Pharma Inc.

LTRN · Nasdaq

Health CareBiotechnologyNot moving yet

LTRN stood above a rising 150-day average in 5 of the last 52 weekly readings, and has been out of that trend for the last 14 weeks. It is 72.9% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 14
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$400K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
39 (+8)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 5 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$625K$0$362KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
D. Jeffrey KeyserDirectorbought48,544at $2.0612 May 2026filed 14 May 2026
D. Jeffrey KeyserDirectorbought48,544at $0.0012 May 2026filed 14 May 2026
Lee Troy SchalopDirectorbought48,544at $2.0612 May 2026filed 14 May 2026
Lee Troy SchalopDirectorbought48,544at $0.0012 May 2026filed 14 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders39+8 on the quarter
New · exited13 · 5
Reported value$12.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Empery Asset Management, LPnew · filed 11 Aug 2026842,669$3.5M+842,669
CM Management, LLCadded · filed 13 Aug 2026500,000$2.1M+250,000+100.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026425,118$1.8M+93,039+28.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026291,039$1.2M+175,039+150.9%
BIOS Capital Management, LPreduced · filed 14 Aug 2026249,397$1.0M-615,038−71.1%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026102,819$429K-8,827−7.9%
VANGUARD FIDUCIARY TRUST COadded · filed 13 Aug 202649,950$208K+343+0.7%
CITADEL ADVISORS LLCnew · filed 14 Aug 202647,895$200K+47,895
Westside Investment Management, Inc.reduced · filed 27 Jul 202647,850$200K-2,200−4.4%
Quadrature Capital Ltdnew · filed 7 Aug 202639,593$165K+39,593
31 Mar 2023 – 30 Jun 2026
182838Mar 23Dec 23Dec 24Sep 25Jun 26

News

Baystreet.ca - Lantern Pharma Down Ahead of Webinarbaystreet.ca · 24 Sep 2026Lantern Pharma Inc.: Lantern Pharma Secures USPTO Notice of Allowance for LP-284 Treatment Patent in Aggressive B-Cell Lymphomasfinanznachrichten.de · 22 Sep 2026New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Globaltennesseedaily.com · 19 Sep 2026New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma (NASDAQ:LTRN), SafeSpace Global (OTCID:SSGC) and FreeCast (NASDAQ:CAST)californiatelegraph.com · 5 Sep 2026New to The Street Broadcasts at 6:30 PM ET Across Bloomberg U.S., Latin America and MENA, Featuring Lantern Pharma, SafeSpace Global and FreeCastfinanznachrichten.de · 5 Sep 2026

Everyone who traded it

D. Jeffrey Keyser Company insiderDirector · last 12 May 20262 · 0
Lee Troy Schalop Company insiderDirector · last 12 May 20261 · 0
David S. Silberstein Company insiderDirector · last 9 Jan 20260 · 0
Maria-Luisa Maccecchini Company insiderDirector · last 9 Jan 20260 · 0
Vijay Chandru Company insiderDirector · last 9 Jan 20260 · 0
David R. Margrave Company insiderChief Financial Officer · last 18 Dec 20250 · 0
Kishor G. Bhatia Company insiderChief Scientific Officer · last 18 Dec 20250 · 0
Bios Fund Ii Qp, Lp Company insider10% owner · last 13 Jun 20250 · 1
Bp Directors, Lp Company insider10% owner · last 13 Jun 20250 · 6
Bios Fund I, Lp Company insider10% owner · last 12 Jun 20250 · 5
Cavu Advisors, Llc Company insider10% owner · last 12 Jun 20250 · 8
Bios Advisors Gp, Llc Company insider10% owner · last 29 May 20250 · 3

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 13 Mar 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$4.4M
Free cash flowFY 2025 · to 31 Dec 2025−$15.7M

Analyst forecasts

No analyst forecasts yet.